- Home
- DAVA vs ALEC Comparison
DAVA vs ALEC Comparison
Compare DAVA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | ALEC |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 275.8M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DAVA | ALEC |
|---|---|---|
| Price | $2.82 | $1.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $13.50 | $4.83 |
| AVG Volume (30 Days) | 187.7K | ★ 1.2M |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $4.07 | $29.87 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $1.09 |
| 52 Week High | $9.88 | $3.40 |
Technical Indicators
Market Signals| Indicator | DAVA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 39.70 |
| Support Level | $2.67 | $1.43 |
| Resistance Level | $3.03 | $2.64 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 9.65 | 6.70 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.